The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Dantrium Intravenous 20 mg powder for solution for injection

Norgine B.V.PA1336/004/003

Main Information

Trade NameDantrium Intravenous 20 mg powder for solution for injection
Active SubstancesDantrolene sodium
Dosage FormPowder for solution for injection
Licence HolderNorgine B.V.
Licence NumberPA1336/004/003

Group Information

ATC CodeM03CA Dantrolene and derivatives
M03CA01 dantrolene


License statusAuthorised
Licence Issued02/12/1980
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back